Watson Pharmaceuticals Inc. (WPI) will become the third-biggest generic drug company worldwide as it changes its name to Actavis and seeks to diversify by using brand-name products to fuel growth. The name change was announced yesterday with the close of Parsippany, New Jersey-based Watson's 4.25 billion euro ($5.51 billion) purchase of Actavis Group hf. It moves Watson from fifth biggest to the top maker of copycat drugs by sales after Teva Pharmaceutical Industries Ltd. (TEVA), based in Petach Tikva, Israel, and Basel, Switzerland-based Novartis AG's Sandoz unit. Chief Executive Officer Paul Bisaro has put Watson on an expansionary path during his tenure, announcing plans to push the...
0 Responses to Watson CEO Looks Past Actavis Deal to Next Growth Plans